Susan Schneider
- Ophthalmology top 0.05%
- Retinal Diseases and Treatments 11
- Ocular Oncology and Treatments 10
- Glaucoma and retinal disorders 5
- Intraocular Surgery and Lenses 4
- Retinal and Optic Conditions 4
-
- Retinal Imaging and Analysis 5
- Molecular Biology top 10%
- Retinal Development and Disorders 4
- Oral Surgery top 5%
- Rheumatology top 10%
-
- Nonmelanoma Skin Cancer Studies 4
- Co-authors
- David M. BrownPeter K. KaiserMark MichelsJeffrey S. HeierRobert Y. KimJudy P. SyG. SoubraneTsontcho Ianchulev
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Susan Schneider
30 papers receiving 4.4k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Ophthalmology 4.2k
- Radiology, Nuclear Medicine and Imaging 3.1k
- Molecular Biology 850
- Oral Surgery 63
- Rheumatology 130
Countries citing papers authored by Susan Schneider
This map shows the geographic impact of Susan Schneider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Schneider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Schneider more than expected).
Fields of papers citing papers by Susan Schneider
This network shows the impact of papers produced by Susan Schneider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Schneider. The network helps show where Susan Schneider may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Susan Schneider, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States | 2019 | 1 |
| 2 | 2018 | 95 | |
| 3 | 2018 | 55 | |
| 4 | 2014 | 2 | |
| 5 | 2013 | 14 | |
| 6 | Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1breakdown → | 2008 | 693 |
| 7 | 2007 | 306 | |
| 8 | 2006 | 9 | |
| 9 | 2005 | 3 | |
| 10 | 2005 | 15 | |
| 11 | 2005 | 14 | |
| 12 | 2005 | 13 | |
| 13 | 2005 | 40 | |
| 14 | 2004 | 13 | |
| 15 | 2003 | 36 | |
| 16 | 2003 | 7 | |
| 17 | 2003 | 1 | |
| 18 | 2003 | 89 | |
| 19 | 1999 | 43 | |
| 20 | 1998 | 13 |
About Susan Schneider
Susan Schneider is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 31 papers that have together received 4.6k indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (11 papers), Ocular Oncology and Treatments (10 papers), Glaucoma and retinal disorders (5 papers), Retinal Imaging and Analysis (5 papers), Intraocular Surgery and Lenses (4 papers), Retinal and Optic Conditions (4 papers), Retinal Development and Disorders (4 papers) and Nonmelanoma Skin Cancer Studies (4 papers). The work is most often cited by research in Ophthalmology (4.2k citations), Radiology, Nuclear Medicine and Imaging (3.1k citations) and Molecular Biology (850 citations). Susan Schneider has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include David M. Brown, Peter K. Kaiser, Mark Michels, Jeffrey S. Heier, Robert Y. Kim, Judy P. Sy, G. Soubrane, Tsontcho Ianchulev, Carl D. Regillo and Prema Abraham.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.